- Open Access
Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells
© Tabuse et al; licensee BioMed Central Ltd. 2011
Received: 3 December 2010
Accepted: 22 May 2011
Published: 22 May 2011
HOX genes encode a family of homeodomain-containing transcription factors involved in the determination of cell fate and identity during embryonic development. They also behave as oncogenes in some malignancies.
In this study, we found high expression of the HOXD9 gene transcript in glioma cell lines and human glioma tissues by quantitative real-time PCR. Using immunohistochemistry, we observed HOXD9 protein expression in human brain tumor tissues, including astrocytomas and glioblastomas. To investigate the role of HOXD9 in gliomas, we silenced its expression in the glioma cell line U87 using HOXD9-specific siRNA, and observed decreased cell proliferation, cell cycle arrest, and induction of apoptosis. It was suggested that HOXD9 contributes to both cell proliferation and/or cell survival. The HOXD9 gene was highly expressed in a side population (SP) of SK-MG-1 cells that was previously identified as an enriched-cell fraction of glioma cancer stem-like cells. HOXD9 siRNA treatment of SK-MG-1 SP cells resulted in reduced cell proliferation. Finally, we cultured human glioma cancer stem cells (GCSCs) from patient specimens found with high expression of HOXD9 in GCSCs compared with normal astrocyte cells and neural stem/progenitor cells (NSPCs).
Our results suggest that HOXD9 may be a novel marker of GCSCs and cell proliferation and/or survival factor in gliomas and glioma cancer stem-like cells, and a potential therapeutic target.
Gliomas, especially glioblastomas (GBMs), are the most malignant primary brain tumors. The median survival of a patient with GBMs is 15 months, and this has improved little by temozolomide treatment. GBMs have a high rate of cellular proliferation and a marked propensity to invade remote brain structures. Such aggressive and invasive growth is the hallmark feature that gives rise to their high morbidity and mortality. A better understanding of the mechanisms underlying the initiation and progression of GBMs at the molecular and cellular levels will open up new opportunities to develop therapeutic strategies.
The growth of many tumors depends on a subset of tumor cells with an extensive capacity for self-renewal, called either cancer stem cells (CSCs) or tumor-initiating cells. Several studies report the presence of CSCs in gliomas[4, 5]. In glioma CSC (GCSC), the expression of some neural stem markers, such as SOX2 and Musashi-1, has been reported[6, 7]. In addition, some markers including CD133 and SSEA-1 (CD15) have been evaluated as GCSC enrichment markers; however, several studies show their limitations as specific markers[10, 11].
Homeobox proteins are master regulators of development and control many cellular processes, including proliferation, apoptosis, cell shape, and cell migration. Homeobox proteins belong to a superfamily, and are encoded by a number of genes, such as SIX, MSX, PAX, LIM, and HOX. Among Homeobox proteins, HOX genes encode transcription factors that act as critical regulators of growth and differentiation, control of cell identity, cellular communication, cell cycle progression, hematopoiesis, and apoptosis in addition to the control of axial patterning during embryogenesis. In humans, 39 HOX genes have been identified and partly or fully redundant functions of HOX genes have also been known.
HOX genes have been reported to be misexpressed in many tumors including lung carcinoma, neuroblastoma, ovarian carcinoma, cervical carcinoma, prostate carcinoma, breast carcinoma, and leukaemia. In addition, epigenetic control of HOX genes in development and diseases have been shown in many studies. In a previous study, we performed restriction landmark genomic scanning (RLGS) with a CpG methylation-sensitive enzyme to identify CpG islands of genes that are differentially methylated in human glioma cells compared with normal lymphocytes to find epigenetically controlled genes in glioma, and identified 12 genes that seem to be regulated by epigenetic gene modification. One of the identified genes was HOXD9. HOXD9 is critical for embryonic segmentation and limb bud patterning during development, but its biological function in human adult tissues has been elusive.
Recently, it was reported that HOXD genes were expressed in neoplastic astrocytes and pediatric low-grade gliomas. However much less is known about the function of HOXD genes especially in gliomas. In this study, we analyzed the expression and function of HOXD9 in human gliomas and found high expression of HOXD9 in GCSCs. HOXD9 contributes to cell proliferation and/or survival in glioma cells and glioma cancer stem-like cells. Thus, HOXD9 may be a new target for the treatment of gliomas based on GCSC population.
Tissue samples and cell lines
All tumor tissue specimens were obtained from patients with glioma who underwent surgery at the Department of Neurosurgery, Keio University School of Medicine and the Department of Neurosurgery, Sainte Anne Hospital, Medical School of Paris Descartes University. Tumors obtained from surgical cases were classified according to the World Health Organization (WHO) criteria as follows: glioblastoma (WHO grade IV), anaplastic astrocytoma (WHO grade III), or diffuse astrocytoma (WHO grade II). Written informed consent was obtained from all patients in the study, which was conducted in accordance with the Institutional Review Board guidelines of Keio University or Paris Descartes University. Human glioma cell lines (U87, SK-MG-1, KNS42, KNS81) were obtained from the American Type Culture Collection (Manassas, VA) and the Japanese Collection of Research Bioresources (Osaka, Japan), and maintained in Dulbecco's modified Eagle's medium (Wako, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS) and antibiotics (50 IU/ml benzyl penicillin G potassium and 100 μg/ml streptomycin sulfate; Meiji, Tokyo, Japan). Side population (SP) and non-SP SK-MG-1 cells were isolated using a flow cytometer (EPIC Altra; Beckman Coulter, Tokyo, Japan) as previously described. Human neural stem/progenitor cells (NSPCs) were cultured as neurospheres (NSPs) in neurosphere culture medium consisting of Neurobasal Medium (Invitrogen, Carlsbad, CA) supplemented with human recombinant (hr) EGF (20 ng/mL; Peprotech, Rocky Hills, NY), hrFGF2 (10 ng/mL; Peprotech), hrLIF (10 ng/mL; Millipore-Japan, Tokyo, Japan), heparin (5 μg/ml; Sigma, St. Louis, MO) and B27 (Invitrogen) as previously described. Primary astrocyte cells were purchased from Takara Bio (Tokyo, Japan). GCSC lines were established from human glioma tissue specimens as described in a previous study.
RNA extraction and quantitative (q) RT-PCR
Total RNA was isolated from human glioma tissues and cell lines using Trizol (Invitrogen). Total RNA from normal tissues was purchased from Clontech (Palo Alto, CA). Synthesis of cDNA was performed using 1 μg of total RNA using Reverse transcriptase XL (AMV) or PrimeScript RT Master Mix (Takara Bio). The primers were designed as follows: for HOXD9, forward primer, 5'-GAGGAGGAGAAGCAGCATTC-3', reverse primer, 5'-TTCTCCAGCTCAAGCGTCTG-3'; for SOX2, forward primer, 5'-ATGGACAGTTACGCGCACA-3', reverse primer, 5'-TGCGAGTAGGACATGCTGTA-3'; for BCL-2, forward primer, 5'-AGGATTGTGGCCTTCTTTGAGT-3', reverse primer, 5'-GCCGGTTCAGGTACTCAGTCAT-3'; for TRAIL forward primer, 5'-CGTGTACTTTACCAACGAGCTGA-3', reverse primer, 5'-ACGGAGTTGCCACTTGACTTG-3'; and for GAPDH, forward primer, 5'-TGAACGGGAAGCTCACTGG-3', reverse primer, 5'-TCCACCACCTGTTGCTGTA-3'. We designed intron-spanning primers to amplify HOXD9 and SOX2. For BCL-2 and TRAIL, respectively, previously tested and optimized primer sets were used as described in Brown (2007) and Williams (2003) . Quantitative RT-PCR analysis was performed with a fluorescent dye, SYBR Green (Applied Biosystems, Foster City, CA), using the ABI prism 7900 HT Sequence Detection System (Applied Biosystems) as previously described. The PCR parameters were as follows: 10 min at 95°C, then 40 cycles of denaturation at 95°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 1 min. The relative gene expression level was normalized to that of GAPDH in each sample and calculated as the threshold cycle (CT) value in each sample divided by the CT value in each reference. The CT value is defined as the value obtained in the PCR cycle when the fluorescence signal increases above the background threshold.
Microarray procedure and data processing
Approximately 106 U87 cells were used for total RNA extraction using the RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. RNA quality was verified with the Bioanalyzer System (Agilent Technologies, Palo Alto, CA) using RNA Nano Chips. RNA (1.5 μg) was processed for hybridization on the Genechip Human Genome U133 Plus 2.0 Expression array (Affymetrix, Santa Clara, CA), which contains over 54,000 probe sets for analyzing the expression level of over 47,000 transcripts and variants, including 38,500 well-characterized human genes. Processing was done according to the manufacturer's recommendations. Except when indicated, all genomic and transcript analysis was carried out using GeneSpring software 7.3.1 (Agilent Technologies). Microarray data were deposited at the NCBI Gene Expression Omnibus (GEO: GSE28618).
GEO data sets (http://www.ncbi.nlm.nih.gov/gds/) were used to analyze mRNA expression microarray data from several brain tumors and normal brain. The following samples were subjected to analysis: normal brain (65 normal human brain tissue samples from ten post-mortem donors, Roth et al., 2006, GSE3526); medulloblastoma (62 samples, Kool et al., 2008, GSE10327); oligodendroglioma grade II and III, astrocytoma grade II and III, and glioblastoma grade IV (157 samples, Sun L et al., 2006, GDS1962). Comparisons were made using the method of Kool et al. The gene expression level of HOXD9 in brain tumors was compared to the expression in normal brain. Statistical values calculated normalized data from MAS 5 algorithm by the Wilcoxon signed rank test.
Bisulfate genomic sequencing
Genomic DNA was purified from each cell line using the Wizard SV Genomic DNA Purification Kit (Promega, Madison, WI). T cells were isolated from peripheral blood mononuclear cells using magnetic beads conjugated to anti-human CD3 (Miltenyi Biotech, Tokyo, Japan). Bisulfate conversion was performed using 0.5-0.7 μg of genomic DNA and the reagents provided in the Qiagen EpiTect Bisulfate kit (Qiagen). The converted DNA was amplified by PCR using the following primers: 5'-GAGGGGAGAATAGTTTTTTT-3' and 5'-CAAACCCAAATCCATATACCC-3'. The PCR products were subcloned into the pGEM-T Easy vector (Promega) and verified by sequencing.
Plasmid construction and transfection
pCMV6-XL5-HOXD9 containing a human full-length cDNA was obtained from Origen Technologies, Inc (Rockville, MD) and subcloned into a pMX-Ig vector (gifted from Dr. T. Kitamura) to generate the pMX-HOXD9. 293T and U87 cells were transfected with a pMX-HOXD9 plasmid using FuGENE HD transfection regent (Roche) according to the manufacturer's protocol.
Western blot analysis
Cell lysates were prepared using the RIPA buffer (25 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS; pH 7.6) containing protease inhibitors (Cocktail Tablet; Roche Diagnostics, Japan). Lysates were centrifuged at 14,000×g for 15 min at 4°C, and the protein concentration of each sample was determined with the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA) with bovine serum albumin as a standard. Identical amounts of the proteins were electrophoresed in 4-10% SDS-PAGE gels and transferred to a nitrocellulose membrane. Blots were blocked with Blocking One™ (Nacalai, Kyoto, Japan) at RT for 60 min, and incubated with either a goat anti-HOXD9 antibody (1:500; Santa Cruz Biotechnology. Inc, CA) and a rabbit anti-GAPDH antibody (1:4,000; Santa Cruz Biotechnology, Inc) overnight at 4°C. After being washed three times in TBST (20 mM Tris-HCl, 150 mM NaCl, and 0.02% tween-20; pH 7.4), the blots were incubated with the secondary antibody conjugated with horseradish peroxidase (1:4,000, anti-rabbit and anti-mouse; Thermo Scientific, Tokyo) for 1 h at room temperature. Signals were detected with a SuperSignal West Femto Maximum Sensivity Subdstrate (Thermo Scientific) and exposed to Hyperfilm (GE Health Care Biosciences). The specificity of HOXD9 antibody was further confirmed by a peptide-absorption assay (Additional file 1, Figure S1), in which the antibody was preincubated with the corresponding peptide antigen by 1:5 weight ratio at 4°C and subjected to the analysis.
Small interfering RNA (siRNA) and transient transfection
siRNA duplexes were designed, synthesized, annealed, and purified by RNAi Co., Ltd (Tokyo, Japan). The sequences of the human HOXD9-specific siRNAs were 5'-GAGUUCGCCUCGUGUAGUUUU-3' (HOXD9 siRNA-1) and 5'- CCACUACGGGAUUAAGCCUGA-3' (HOXD9 siRNA-2). As a control, we used a non-silencing siRNA with the sequence 5'-GUACCGCACGUCAUUCGUAUC-3'. U87 or SK-MG-1 SP cells (5-6 × 104 cells/ml) were seeded in triplicate in tissue culture dishes (24-well or 96-well) 24 h prior to siRNA transfection. Control or HOXD9 siRNAs were transfected at a concentration of 50 nM using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions.
Cell proliferation assay
Following siRNA transfection, cells were harvested by trypsinization and the total number of cells was counted by trypan blue exclusion under a phase-contrast microscope. A cell viability assay was performed using the Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega) according to the manufacturer's protocol, using a luminometer (Wallac ARVO 1420 multilabel counter; WALLAC OY, Truku, Finland). Cell cycle analysis for live cells was performed using flow cytometry. siRNA-treated cells were stained with Vybrant DyeCycle Violet Stain (Invitrogen) for 30 min at 37°C according to the manufacturer's protocol and then subjected to flow cytometry (Gallios; Beckman Coulter). Raw data were analyzed using Multicycle for Windows (Beckman Coulter).
Colony formation assay
48 h after siRNA transfection, cells (2 × 104 cells) were mixed with 2 ml of culture medium containing 0.4% agar and 10% FCS and then plated on 2 ml of the bottom layer containing 0.6% agar with 10% FCS in each well of a 6-well plate. Each experiment was performed in triplicate. After 3 weeks culture, colonies were counted after staining with MTT 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide.
Caspase 3/7 activity in siRNA-transfected cells was measured using the Caspase-Glo 3/7 assay kit (Promega) according to the manufacturer's instructions. U87 cells were plated in 96-well plates at a seeding density of 6 × 103 cells/well, and caspase activity was assayed 48 h after siRNA transfection. To differentiate between apoptotic and necrotic cell death, siRNA-transfected cells (1 × 105 cells/ml) were stained with 5 μl Annexin-V antibody and 5 μl 7-AAD using an Annexin V-FITC/7-AAD-staining kit (Beckman Coulter), placed on ice for 10 min in the dark, and then analyzed by flow cytometry(EPICS XL; Beckman Coulter).
Time-lapse cell imaging
Cells were transfected with control siRNA, HOXD9 siRNA-1 and HOXD9 siRNA-2. 24 h after transfection, 10,000 cells were plated on 24-well glass plates (IWAKI, Tokyo, Japan) and imaged using a NIKON TE2000-E microscope equipped with ×200 magnification lens (Nikon, Tokyo, Japan). The microscope stage was enclosed by a plastic air curtain and heated to 37°C. Time-lapse recordings were taken every 5 minutes for 96 h and analyzed using the image analysis software MetaMorph (Molecular Devices, Downingtown, PA). The cell division time of cells transfected with siRNAs was determined using the time-lapse images.
Paraffin-embedded tissue sections (5 μm) were deparaffinized in xylene and rehydrated. The sections were treated with a heat-based antigen retrieval method using a citrate solution (pH 6.0, 10 mM). Nonspecific binding of antibodies was blocked by incubation in 5% rabbit serum in 0.01 M PBS for 30 min. The slides were then incubated with goat anti-human HOXD9 polyclonal antibody (1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) diluted with 0.02% BSA in 0.01 M PBS overnight at 4°C in a humidified box. The slides were then incubated with a secondary antibody (Universal Immuno-peroxidase Polymer, Anti-goat; Histofine Simple Stain MAX PO (G), Nichirei Corporation, Tokyo, Japan) for 30 min at 37°C, and horseradish peroxidase labeling was visualized using 3,3'-diamonobenzidene (DAB). The sections were then lightly counterstained with hematoxylin. Each step was followed by three washes in PBS. To evaluate the proliferation of tumor cells, the same sections were stained with the monoclonal antibody MIB-1 (1:200; DAKO Japan, Kyoto, Japan) that recognizes the Ki-67 protein. The proliferating cell indexes were analyzed for >1000 tumor cells in more than three areas expressing the highest number of immunopositive nuclei. The analysis was performed using a digital camera (DXM-1200) attached to a microscope (Nikon) and ACT-1 software (Nikon). Immunohistochemical staining was performed in 29 glioma cases (5 diffuse astrocytomas, 11 anaplastic astrocytomas and 13 glioblastomas).
The results are presented as mean values ± S.D. Data were analyzed using a Student's t test with P < 0.05 considered statistically significant.
Analysis of HOXD9 gene expression in gliomas
Immunohistochemical analysis of HOXD9 in gliomas
Association of HOXD9 expression and MIB-1 index in glioma tissues
WHO grade IV
WHO grade III
WHO grade II
Gene silencing of HOXD9 decreases cell proliferation of glioma U87 cells
Gene silencing of HOXD9 induces apoptosis in U87 glioma cells
HOXD9 is involved in the proliferation of SK-MG-1 SP cells
HOXD9 expression in human GCSCs
We cultured human GCSCs as glioma spheres from glioma surgical specimens and established five cell lines as described in our previous study. SOX2, a known neural stem/progenitor cell (NSPC) marker, is also expressed in gliomas and GCSCs. We performed qRT-PCR to examine the expression of HOXD9 and SOX2 in GCSCs compared with normal primary astrocytes and NSPCs derived from fetal brain and cultured as neurospheres. The expression of SOX2 and HOXD9 in GCSCs was higher than that in normal astrocytes and NSPCs. Also, HOXD9 expression was higher than SOX2 expression in some GCSCs (Figure 6C).
This is the first study examining the function of HOXD9 in gliomas. We found that HOXD9 was more highly expressed in gliomas and GCSCs and that gene silencing of HOXD9 reduced the proliferation of both glioma cells and glioma cancer stem-like cell population.
The expression of homeobox family genes is generally restricted during embryogenesis. Recently, it was reported that HOXD9 is expressed in murine neural tubes and neural crest cells during development. In this study, we observed the high expression of HOXD9 in normal adult human kidney and testis. The misexpression of homeobox transcription factor genes has also been reported in cancer tissues; for example, HOXA1 and Six1 transform mammary epithelial cells[34, 35], and Msx1 and Cdx transform myoblasts and intestinal epithelial cells, respectively. Although the mechanisms underlying the misexpression of homeobox transcription factor genes in cancer remain elusive, the deregulation of non-coding RNA expression and/or changes in the methylation status of the promoters may be involved. Recently, it has been reported that non-coding RNA residing in the HOXC locus could act in trans to regulate transcription of the HOXD locus with the Polycomb-repressive complex 2 (PRC2). HOXD11 and HOXD12 are regulated by the Polycomb group proteins during embryonic stem cell differentiation. We performed bisulfate sequencing to compare the methylation status of the HOXD9 promoter in U87 cells compared with normal human T cells and NSPCs. Hypermethylation of CpG islands was observed in the HOXD9 promoter region in U87 cells compared to T cells and NSPCs when HOXD9 gene expression was high (Additional file 3, Figure S3). This relationship between gene expression and methylation status has also been observed in HOXB family genes in small-cell lung cancer. Hypermethylation of CpG islands in promoter regions has been reported for many genes, including the HOXC and HOXD cluster genes associated with HOXD9 in human astrocytomas[39, 41]. It is difficult to understand why hypermethylation correlates with increased rather than decreased gene expression. In the future, it may be important to evaluate the methylation status of HOXD9 in the whole genome, as well as histone modification in gliomas and GCSCs compared with normal brain and NSPCs using the tiling array system and/or a next-generation sequencer. Thus, the analyses of epigenetic regulation of HOXD9 gene expression in gliomas and GCSCs related to Polycomb proteins and non-coding RNA will be an important issue in the near future.
We showed that gene knockdown of HOXD9 reduces the proliferation of U87, KNS-42, and KNS-81 glioma cells and glioma cancer stem-like cells; SK-MG-1 SP cells. So far, HOXD9 is reported to be involved in the regulation of cell proliferation in rheumatoid arthritis and carcinogenesis, indicating that HOXD9 may contribute to cell proliferation in HOXD9-expressing cells in gliomas including GCSCs In our preliminary experiment, transiently over-expressed HOXD9 increased the S-phase cell population of U87 cells in cell cycle analysis (data not shown). In this study, gene silencing of HOXD9 induced apoptosis and reduced the expression of BCL-2 in glioma cells, indicating that HOXD9 may support the cell survival. Furthermore, immunohistochemical studies showed no apparent correlation between HOXD9 expression level and WHO grade or MIB-1 index, suggesting that HOXD9 may be expressed in primitive cancer cell populations, including GCSCs in vivo. As for the upstream factors of HOXD9, it has been reported that HOXD9 expression is induced by Wnt signaling, which is a maintenance factor for neural stem cells and neural crest cells, suggesting that HOXD9 may act as a maintenance or survival factor for GCSCs undercontrol of Wnt signaling. HOXB1 also supports the maintenance and expansion of neural progenitor cells, and HOXB4 may expand hematopoietic stem cells. Taken together, these results indicate that some homeobox proteins including HOXD9 may contribute to cancer stem cell maintenance in addition to the cell proliferation and/or survival.
In the present study, we demonstrated that HOXD9 was highly expressed in glioma cells and GCSCs cultured from patient specimens compared with human NSPCs and astrocytes. To date, drug development for targeting cancer stem cells is an important issue in cancer therapy. Therefore, it is very important for this purpose to find targets expressed in cancer stem cells with a high specificity. In this point, HOXD9 may be an ideal therapeutic target for the treatment of gliomas because the expression in NSPCs and astrocytes is lower than GCSCs, suggesting that HOXD9 targeted therapy may have a therapeutic index. In fact, knockdown of HOXD9 decreased the proliferation of glioma cancer stem-like cells in vitro, supporting the idea. Recently, it has been reported that HOXA9 decreases apoptosis and increases cell proliferation in glioma cells by epigenetic control and the expression of HOXA10 in GBM-derived spheres. Thus, it may be intriguing to study the detailed analysis of HOX families in GCSCs in the future for the development of drug discovery targeted for GCSCs.
HOXD9 may be useful as a marker for glioma and GCSCs, and therapies targeting HOXD9 should be considered for further development.
We thank the Collaborative Research Resources, Keio University School of Medicine (Keio-Med Open Access Facility) for technical assistance. We also thank Ms. Sayaka Teramoto, Ms. Reiko Kuwahara, and Mr. K. Morii (Keio University School of Medicine) for technical assistance, Dr. T. Kitamura (Tokyo University) for the gift of plasmid pMX-Ig, and Dr. Marcel Kool (Department of Human Genetics, Academic Medical Center, Amsterdam) for microarray data mining.
The authors would also like to acknowledge Dr. Kesari Santosh (University of California, San Diego) for critical reading of the manuscript. HC: equipe labelisee La Ligue 2007.
- Benjamin R, Capparella J, Brown A: Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J. 2003, 9: 82-90. 10.1097/00130404-200303000-00003View ArticlePubMedGoogle Scholar
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330View ArticlePubMedGoogle Scholar
- Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038/35102167View ArticlePubMedGoogle Scholar
- Vescovi AL, Galli R, Reynolds BA: Brain tumour stem cells. Nat Rev Cancer. 2006, 6: 425-436. 10.1038/nrc1889View ArticlePubMedGoogle Scholar
- Stiles CD, Rowitch DH: Glioma stem cells: a midterm exam. Neuron. 2008, 58: 832-846. 10.1016/j.neuron.2008.05.031View ArticlePubMedGoogle Scholar
- Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G: SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells. 2009, 27: 40-48. 10.1634/stemcells.2008-0493View ArticlePubMedGoogle Scholar
- Thon N, Damianoff K, Hegermann J, Grau S, Krebs B, Schnell O, Tonn JC, Goldbrunner R: Presence of pluripotent CD133(+) cells correlates with malignancy of gliomas. Mol Cell Neurosci. 2010, 43: 51-59. 10.1016/j.mcn.2008.07.022View ArticlePubMedGoogle Scholar
- Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63: 5821-5828.PubMedGoogle Scholar
- Son MJ, Woolard K, Nam DH, Lee J, Fine HA: SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009, 4: 440-452. 10.1016/j.stem.2009.03.003View ArticlePubMedGoogle Scholar
- Patru C, Romao L, Varlet P, Coulombel L, Raponi E, Cadusseau J, Renault-Mihara F, Thirant C, Leonard N, Bernheim A: CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer. 2010, 10: 66- 10.1186/1471-2407-10-66PubMed CentralView ArticlePubMedGoogle Scholar
- Prestegarden L, Enger PO: Cancer Stem Cells in the Central Nervous System - A Critical Review. Cancer Res. 2010, 70: 8255-8258. 10.1158/0008-5472.CAN-10-1592View ArticlePubMedGoogle Scholar
- Doboule D: Guidebook to the Homeobox Genes. 1994, New York: Oxford Univ. PressGoogle Scholar
- Carroll SB: Homeotic genes and the evolution of arthropods and chordates. Nature. 1995, 376: 479-485. 10.1038/376479a0View ArticlePubMedGoogle Scholar
- Shah N, Sukumar S: The Hox genes and their roles in oncogenesis. Nat Rev Cancer. 2010, 10: 361-371. 10.1038/nrc2826View ArticlePubMedGoogle Scholar
- Barber BA, Rastegar M: Epigenetic control of Hox genes during neurogenesis, development, and disease. Ann Anat. 2010, 192: 261-274. 10.1016/j.aanat.2010.07.009View ArticlePubMedGoogle Scholar
- Ohashi Y, Ueda M, Kawase T, Kawakami Y, Toda M: Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning. Oncogene. 2004, 23: 7772-7779. 10.1038/sj.onc.1208058View ArticlePubMedGoogle Scholar
- Fromental-Ramain C, Warot X, Lakkaraju S, Favier B, Haack H, Birling C, Dierich A, Dollé P, Chambon P: Specific and redundant functions of the paralogous Hoxa-9 and Hoxd-9 genes in forelimb and axial skeleton patterning. Development. 1996, 122: 461-472.PubMedGoogle Scholar
- Morgan BA, Tabin C: Hox genes and growth: early and late roles in limb bud morphogenesis. Dev Suppl. 1994, 181-186.Google Scholar
- Abdel-Fattah R, Xiao A, Bomgardner D, Pease CS, Lopes MB, Hussaini IM: Differential expression of HOX genes in neoplastic and non-neoplastic human astrocytes. J Pathol. 2006, 209: 15-24. 10.1002/path.1939View ArticlePubMedGoogle Scholar
- Buccoliero AM, Castiglione F, Degl'Innocenti DR, Ammanati F, Giordano F, Sanzo M, Mussa F, Genitori L, Taddei GL: Hox-D genes expression in pediatric low-grade gliomas: real-time-PCR study. Cell Mol Neurobiol. 2009, 29: 1-6. 10.1007/s10571-008-9282-1View ArticlePubMedGoogle Scholar
- Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002, 61: 215-225. discussion 226-219PubMedGoogle Scholar
- Fukaya R, Ohta S, Yamaguchi M, Fujii H, Kawakami Y, Kawase T, Toda M: Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1. Cancer Lett. 2009, 291 (2): 150-7.View ArticlePubMedGoogle Scholar
- Hattori Y, Ohta S, Hamada K, Yamada-Okabe H, Kanemura Y, Matsuzaki Y, Okano H, Kawakami Y, Toda M: Identification of a neuron-specific human gene, KIAA1110, that is a guanine nucleotide exchange factor for ARF1. Biochem Biophys Res Commun. 2007, 364: 737-742. 10.1016/j.bbrc.2007.10.041View ArticlePubMedGoogle Scholar
- Brown JE, Dunmore SJ: Leptin decreases apoptosis and alters BCL-2: Bax ratio in clonal rodent pancreatic beta-cells. Diabetes Metab Res Rev. 2007, 23: 497-502. 10.1002/dmrr.726View ArticlePubMedGoogle Scholar
- Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res. 2003, 9: 931-946.PubMedGoogle Scholar
- Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster AC, Zlotnik A: Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics. 2006, 7: 67-80. 10.1007/s10048-006-0032-6View ArticlePubMedGoogle Scholar
- Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008, 3: e3088- 10.1371/journal.pone.0003088PubMed CentralView ArticlePubMedGoogle Scholar
- Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006, 9: 287-300. 10.1016/j.ccr.2006.03.003View ArticlePubMedGoogle Scholar
- Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T, Ushio Y, Saya H: Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene. 2004, 23: 6548-6558. 10.1038/sj.onc.1207873View ArticlePubMedGoogle Scholar
- Hetschko H, Voss V, Horn S, Seifert V, Prehn JH, Kogel D: Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol. 2008, 86: 265-272. 10.1007/s11060-007-9472-6View ArticlePubMedGoogle Scholar
- Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K: Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell. 2009, 5: 504-514. 10.1016/j.stem.2009.08.018View ArticlePubMedGoogle Scholar
- Kanemura Y, Mori H, Kobayashi S, Islam O, Kodama E, Yamamoto A, Nakanishi Y, Arita N, Yamasaki M, Okano H: Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity. J Neurosci Res. 2002, 69: 869-879. 10.1002/jnr.10377View ArticlePubMedGoogle Scholar
- Ishikawa S, Ito K: Plasticity and regulatory mechanisms of Hox gene expression in mouse neural crest cells. Cell Tissue Res. 2009, 337: 381-391. 10.1007/s00441-009-0827-5View ArticlePubMedGoogle Scholar
- Radisky DC: Defining a role for the homeoprotein Six1 in EMT and mammary tumorigenesis. J Clin Invest. 2009, 119: 2528-2531. 10.1172/JCI40555PubMed CentralView ArticlePubMedGoogle Scholar
- Mohankumar KM, Perry JK, Kannan N, Kohno K, Gluckman PD, Emerald BS, Lobie PE: Transcriptional activation of signal transducer and activator of transcription (STAT) 3 and STAT5B partially mediate homeobox A1-stimulated oncogenic transformation of the immortalized human mammary epithelial cell. Endocrinology. 2008, 149: 2219-2229. 10.1210/en.2007-1320View ArticlePubMedGoogle Scholar
- Bendall AJ, Ding J, Hu G, Shen MM, Abate-Shen C: Msx1 antagonizes the myogenic activity of Pax3 in migrating limb muscle precursors. Development. 1999, 126: 4965-4976.PubMedGoogle Scholar
- Gao N, White P, Kaestner KH: Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. Dev Cell. 2009, 16: 588-599. 10.1016/j.devcel.2009.02.010PubMed CentralView ArticlePubMedGoogle Scholar
- Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, Chang HY: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007, 129: 1311-1323. 10.1016/j.cell.2007.05.022PubMed CentralView ArticlePubMedGoogle Scholar
- Woo CJ, Kharchenko PV, Daheron L, Park PJ, Kingston RE: A region of the human HOXD cluster that confers polycomb-group responsiveness. Cell. 2010, 140: 99-110. 10.1016/j.cell.2009.12.022PubMed CentralView ArticlePubMedGoogle Scholar
- Flagiello D, Poupon MF, Cillo C, Dutrillaux B, Malfoy B: Relationship between DNA methylation and gene expression of the HOXB gene cluster in small cell lung cancers. FEBS Lett. 1996, 380: 103-107. 10.1016/0014-5793(96)00017-8View ArticlePubMedGoogle Scholar
- Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP: CpG island hypermethylation in human astrocytomas. Cancer Res. 2010, 70: 2718-2727. 10.1158/0008-5472.CAN-09-3631PubMed CentralView ArticlePubMedGoogle Scholar
- Nguyen NC, Hirose T, Nakazawa M, Kobata T, Nakamura H, Nishioka K, Nakajima T: Expression of HOXD9 in fibroblast-like synoviocytes from rheumatoid arthritis patients. Int J Mol Med. 2002, 10: 41-48.PubMedGoogle Scholar
- Liu DB, Gu ZD, Cao XZ, Liu H, Li JY: Immunocytochemical detection of HoxD9 and Pbx1 homeodomain protein expression in Chinese esophageal squamous cell carcinomas. World J Gastroenterol. 2005, 11: 1562-1566.PubMed CentralView ArticlePubMedGoogle Scholar
- Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR, Nusse R: Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003, 423: 448-452. 10.1038/nature01611View ArticlePubMedGoogle Scholar
- Garcia-Castro MI, Marcelle C, Bronner-Fraser M: Ectodermal Wnt function as a neural crest inducer. Science. 2002, 297: 848-851.PubMedGoogle Scholar
- Gouti M, Gavalas A: Hoxb1 controls cell fate specification and proliferative capacity of neural stem and progenitor cells. Stem Cells. 2008, 26: 1985-1997. 10.1634/stemcells.2008-0182View ArticlePubMedGoogle Scholar
- Lu SJ, Feng Q, Ivanova Y, Luo C, Li T, Li F, Honig GR, Lanza R: Recombinant HoxB4 fusion proteins enhance hematopoietic differentiation of human embryonic stem cells. Stem Cells Dev. 2007, 16: 547-559. 10.1089/scd.2007.0002View ArticlePubMedGoogle Scholar
- Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB: Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009, 8: 806-823. 10.1038/nrd2137View ArticlePubMedGoogle Scholar
- Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J: Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res. 2010, 70: 453-462. 10.1158/0008-5472.CAN-09-2189PubMed CentralView ArticlePubMedGoogle Scholar
- Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC: Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008, 26: 3015-3024. 10.1200/JCO.2007.15.7164View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.